Extrapolation of in vitro metabolic and P-glycoprotein-mediated transport data to in vivo by modeling and simulations

Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges

Volumn , Issue , 2010, Pages 299-315

  Kato, Motohiro ^a   Shitara, Yoshihisa ^b   Kitajima, Masato ^c   Tachibana, Tatsuhiko ^a   Ishigai, Masaki ^a   Horie, Toshiharu ^b   Sugiyama, Yuichi ^d  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c FUJITSU LABORATORIES LTD   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955275378     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0840-7_12     Document Type: Chapter

References (23)

1. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
2. Food and Drug Administration (2006) Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling (draft guidance).
3. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H and Lesko LJ (2008) New era in drug interaction evaluation: US food and drug administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
4. Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue S, Takasaki W, Ikeda T, Komai T, Ito K and Sugiyama Y (2001) Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res 18:622-631.
5. Isoherranen N, Kunze KL, Allen KE, Nelson WL and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131.
6. Ito K, Brown HS and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
7. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T and Sugiyama Y (2002) Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. AAPS Pharm Sci 4:E25.
8. Kato M (2008) Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet 23:87-94.
9. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K and Sugiyama Y (2003a) The intestinal firstpass metabolism of substrates of CYP3A4 and P-glycoprotein- quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
10. Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T and Sugiyama Y (2008) The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res 25:1891-1901.
11. Kato M, Tachibana T, Ito K and Sugiyama Y (2003b) Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Drug Metab Pharmacokinet 18:121-127.
12. Lin JH, Chiba M and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol Rev 51:135-158.
13. Ministry of Health, Labour and Welfare, Japan (2001) Methods of drug interaction studies: notification No. 813 of the pharmaceutical affair bureau 2001 Japan.
14. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
15. Ohno Y, Hisaka A and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696.
16. Rostami-Hodjegan A, Tucker GT. (2004) "In silico" simulations to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions. Drug Discov Today: Technol 1:441-448.
17. Shitara Y, Hirano M, Sato H and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
18. Shitara Y, Horie T and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
19. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
20. Shitara Y, Sato H and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
21. Tachibana T, Kato M, Watanabe T, Mitsui T and Sugiyama Y (2009) A method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica in press.
22. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
23. Zhang L, Zhang YD, Strong JM, Reynolds KS and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.